Evidence map›Paper›PMID 30096199›Full record

ArticlePloS one2018

Equity of antiretroviral treatment use in high HIV burden countries: Analyses of data from nationally-representative surveys in Kenya and South Africa.

Sizulu Moyo, Peter W Young, Eleanor Gouws, Inbarani Naidoo, Joyce Wamicwe, Irene Mukui, Kimberly Marsh, Ehimario U Igumbor, Andrea A Kim, Thomas Rehle

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey.International journal of environmental research and public health · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sizulu MoyoHIV/AIDS, STIs and TB programme, Human Sciences Research Council, Cape Town, South Africa.
Peter W YoungU.S. Centers for Disease Control and Prevention, Division of Global HIV & TB, Nairobi, Kenya.ORCID 0000-0002-7432-2876
Eleanor GouwsThe Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
Inbarani NaidooUniversity of Cape Town, School of Public Health and Family Medicine, Cape Town, South Africa.
Joyce WamicweMinistry of Health, National AIDS & STI Control Programme, Nairobi, Kenya.
Irene MukuiMinistry of Health, National AIDS & STI Control Programme, Nairobi, Kenya.
Kimberly MarshThe Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland.
Ehimario U IgumborU.S. Centers for Disease Control and Prevention, Division of Global HIV & TB, Pretoria, South Africa.
Andrea A KimU.S. Centers for Disease Control and Prevention, Division of Global HIV & TB, Atlanta, Georgia, United States of America.
Thomas RehleUniversity of Cape Town, School of Public Health and Family Medicine, Cape Town, South Africa.

Funding

CGH CDC HHS U19 GH000069PEPFAR
6 · The paper itself

Abstract

objectiveTo assess changes and equity in antiretroviral therapy (ART) use in Kenya and South Africa.

methodsWe analysed national population-based household surveys conducted in Kenya and South Africa between 2007 and 2012 for factors associated with lack of ART use among people living with HIV (PLHIV) aged 15-64 years. We considered ART use to be inequitable if significant differences in use were found between groups of PLHIV (e.g. by sex).

findingsART use among PLHIV increased from 29.3% (95% confidence interval [CI]: 22.8-35.8) to 42.5% (95%CI: 37.4-47.7) from 2007 to 2012 in Kenya and 17.4% (95%CI: 14.2-20.9) to 30.3% (95%CI: 27.2-33.6) from 2008 to 2012 in South Africa. In 2012, factors independently associated with lack of ART use among adult Kenyan PLHIV were rural residency (adjusted odds ratio [aOR] 1.98, 95%CI: 1.23-3.18), younger age (15-24 years: aOR 4.25, 95%CI: 1.7-10.63, and 25-34 years: aOR 5.16, 95%CI: 2.73-9.74 versus 50-64 years), nondisclosure of HIV status to most recent sex partner (aOR 2.41, 95%CI: 1.27-4.57) and recent recreational drug use (aOR 2.50, 95%CI: 1.09-5.77). Among South African PLHIV in 2012, lack of ART use was significantly associated with younger age (15-24 years: aOR 4.23, 95%CI: 2.56-6.70, and 25-34 years: aOR 2.84, 95%CI: 1.73-4.67, versus 50-64 years), employment status (aOR 1.61, 95%CI: 1.16-2.23 in students versus unemployed), and recent recreational drug use (aOR 4.56, 95%CI: 1.79-11.57).

conclusionAlthough we found substantial increases in ART use in both countries over time, we identified areas needing improvement including among rural Kenyans, students in South Africa, and among young people and drug users in both countries.

Indexed as

Healthcare DisparitiesAdolescentAdultAnti-HIV AgentsFemaleHealth Services AccessibilityHIV InfectionsHumansKenyaMaleMiddle AgedRisk FactorsSouth AfricaYoung AdultAnti-HIV Agents

Identifiers

PMID30096199
PMCPMC6086417

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.